Type i to type II ovarian carcinoma progression: Mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer

American Journal of Pathology

Volumn 182, Issue 4, 2013, Pages 1391-1399

  Wu, Rong ^a   Baker, Suzanne J ^b   Hu, Tom C ^a   Norman, Kyle M ^a   Fearon, Eric R ^a   Cho, Kathleen R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYTOKERATIN 8; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR PAX8; UVOMORULIN; WNT PROTEIN; WNT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM; FEMALE; GENE ACTIVATION; GENE DELETION; GENE FREQUENCY; GENE INACTIVATION; GENOTYPE; METASTASIS; MISSENSE MUTATION; MOUSE; NONHUMAN; OVARIAN SURFACE EPITHELIUM; OVARY CANCER; OVARY CARCINOMA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOMETRIUM; EPITHELIAL CELLS; FEMALE; HUMANS; HYPERPLASIA; MICE; MUTANT PROTEINS; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875205987     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.12.031     Document Type: Article

References (54)

1. R.J. Kurman, and IeM. Shih Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2008 151 160
2. IeM. Shih, and R.J. Kurman Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am J Pathol 164 2004 1511 1518
3. J.D. Seidman, K.R. Cho, B.M. Ronnett, and R.J. Kurman Surface epithelial tumors of the ovary. Blaustein's pathology of the female genital tract, ed 6 R.J. Kurman, L.H. Ellenson, R.M. Ronnett, 2011 Springer New York 679 784
4. A.A. Ahmed, D. Etemadmoghadam, J. Temple, A.G. Lynch, M. Riad, R. Sharma, C. Stewart, S. Fereday, C. Caldas, A. Defazio, D. Bowtell, and J.D. Brenton Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 2010 49 56
5. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat Rev Cancer 10 2010 803 808
6. K.R. Cho, and I.M. Shih Ovarian cancer Annu Rev Pathol Mech Dis 4 2009 287 313
7. N. Sangha, R. Wu, R. Kuick, S. Powers, D. Mu, D. Fiander, K. Yuen, H. Katabuchi, H. Tashiro, E.R. Fearon, and K.R. Cho Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations Neoplasia 10 2008 1362 1372
8. C.G.A.R. Network integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
9. D.W. Kindelberger, Y. Lee, C. Feltmate, M. Callahan, E. Garner, R.S. Berkowitz, M.G. Muto, and C.P. Crum Coexisting tubal intraepithelial carcinoma (TIC) and ovarian serous carcinoma: frequency and implications for the fallopian tube as a source of "ovarian" serous neoplasia Lab Invest 86 Supplement 2006 184A
10. D.W. Kindelberger, Y. Lee, A. Miron, M.S. Hirsch, C. Feltmate, F. Medeiros, M.J. Callahan, E.O. Garner, R.W. Gordon, C. Birch, R.S. Berkowitz, M.G. Muto, and C.P. Crum Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 2007 161 169
11. C.P. Crum, R. Drapkin, A. Miron, T.A. Ince, M. Muto, D.W. Kindelberger, and Y. Lee The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 2007 3 9
12. E.A. Jarboe, E.S. Pizer, A. Miron, N. Monte, G.L. Mutter, and C.P. Crum Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma Mod Pathol 22 2009 345 350
13. W.G. McCluggage My approach to and thoughts on the typing of ovarian carcinomas J Clin Pathol 61 2008 152 163
14. R. Wu, N. Hendrix-Lucas, R. Kuick, Y. Zhai, D.R. Schwartz, A. Akyol, S. Hanash, D.M. Misek, H. Katabuchi, B.O. Williams, E.R. Fearon, and K.R. Cho Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/B-catanin and PI3K/Pten signaling pathways Cancer Cell 11 2007 321 333
15. T. Okuda, J. Otsuka, A. Sekizawa, H. Saito, R. Makino, M. Kushima, A. Farina, Y. Kuwano, and T. Okai p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer Gynecol Oncol 88 2003 318 325
16. M.M. Leitao, R.A. Soslow, R.N. Baergen, N. Olvera, C. Arroyo, and J. Boyd Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma Gynecol Oncol 93 2004 301 306
17. J. Willner, K. Wurz, K.H. Allison, V. Galic, R.L. Garcia, B.A. Goff, and E.M. Swisher Alternate molecular genetic pathways in ovarian carcinomas of common histological types Hum Pathol 38 2007 607 613
18. P. Strang, B. Nordstom, S. Nilsson, R. Bergstrom, and B. Tribukait Mutant p53 protein as a predictor of survival in endometrial carcinoma Eur J Cancer 32A 1996 598 602
19. S. Ogino, K. Nosho, G.J. Kirkner, K. Shima, N. Irahara, S. Kure, A.T. Chan, J.A. Engelman, P. Kraft, L.C. Cantley, E.L. Giovannucci, and C.S. Fuchs PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 27 2009 1477 1484
20. S.Y. Li, M. Rong, F. Grieu, and B. Iacopetta PIK3CA mutations in breast cancer are associated with poor outcome Breast Cancer Res Treat 96 2006 91 95
21. X. Liao, T. Morikawa, P. Lochhead, Y. Imamura, A. Kuchiba, M. Yamauchi, K. Nosho, Z.R. Qian, R. Nishihara, J.A. Meyerhardt, C.S. Fuchs, and S. Ogino Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review Clin Cancer Res 18 2012 2257 2268
22. L. Catasus, A. Gallardo, M. Cuatrecasas, and J. Prat PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters Mod Pathol 21 2008 131 139
23. J. Woenckhaus, K. Steger, K. Sturm, K. Munstedt, F.E. Franke, and I. Fenic Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer Virchows Arch 450 2007 387 395
24. Y. Wang, A. Helland, R. Holm, G.B. Kristensen, and A.L. Borresen-Dale PIK3CA mutations in advanced ovarian carcinomas Hum Mutat 25 2005 322
25. M. Rahman, K. Nakayama, M.T. Rahman, N. Nakayama, M. Ishikawa, A. Katagiri, K. Iida, S. Nakayama, Y. Otsuki, I.M. Shih, and K. Miyazaki Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma Hum Pathol 43 2012 2197 2206
26. M.R. Quddus, L.B. Rashid, K. Hansen, C.J. Sung, and W.D. Lawrence High-grade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23-year-old woman Histopathology 54 2009 771 773
27. R. Dehari, R.J. Kurman, S. Logani, and M. Shih Ie The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis Am J Surg Pathol 31 2007 1007 1012
28. C. Boyd, and W.G. McCluggage Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon Am J Surg Pathol 36 2011 368 375
29. R.L. Parker, P.B. Clement, D.J. Chercover, T. Sornarajah, and C.B. Gilks Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases Int J Gynecol Pathol 23 2004 265 272
30. G. Robinson, M. Parker, T.A. Kranenburg, C. Lu, X. Chen, and L. Ding Novel mutations target distinct subgroups of medulloblastoma Nature 488 2012 43 48
31. R. Wu, T. Hu, A. Rehemtulla, E.R. Fearon, and K.R. Cho Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma Clin Cancer Res 17 2011 7359 7372
32. K.P. Olive, D.A. Tuveson, Z.C. Ruhe, B. Yin, N.A. Willis, R.T. Bronson, D. Crowley, and T. Jacks Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome Cell 119 2004 847 860
33. A. de Vries, E.R. Flores, B. Miranda, H.M. Hsieh, C.T. van Oostrom, J. Sage, and T. Jacks Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function Proc Natl Acad Sci U S A 99 2002 2948 2953
34. G. Lozano The oncogenic roles of p53 mutants in mouse models Curr Opin Genet Dev 17 2007 66 70
35. A.K. Sood, J.I. Sorosky, M. Dolan, B. Anderson, and R.E. Buller Distant metastases in ovarian cancer: association with p53 mutations Clin Cancer Res 5 1999 2485 2490
36. J. Jonkers, R. Meuwissen, H. van der Gulden, H. Peterse, M. van der Valk, and A. Berns Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer Nat Genet 29 2001 418 425
37. K.R. Cho Ovarian cancer update: lessons from morphology, molecules, and mice Arch Pathol Lab Med 133 2009 1775 1781
38. M.L. Rudd, J.C. Price, S. Fogoros, A.K. Godwin, D.C. Sgroi, M.J. Merino, and D.W. Bell A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas Clin Cancer Res 17 2011 1331 1340
39. A. Hollestelle, F. Elstrodt, J.H. Nagel, W.W. Kallemeijn, and M. Schutte Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines Mol Cancer Res 5 2007 195 201
40. M. Gymnopoulos, M.A. Elsliger, and P.K. Vogt Rare cancer-specific mutations in PIK3CA show gain of function Proc Natl Acad Sci U S A 104 2007 5569 5574
41. P.K. Vogt, J.R. Hart, M. Gymnopoulos, H. Jiang, S. Kang, A.G. Bader, L. Zhao, and A. Denley Phosphatidylinositol 3-kinase: the oncoprotein Curr Top Microbiol Immunol 347 2010 79 104
42. S. Liang, N. Yang, Y. Pan, S. Deng, X. Lin, X. Yang, D. Katsaros, K.F. Roby, T.C. Hamilton, D.C. Connolly, G. Coukos, and L. Zhang Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation PLoS One 4 2009 e4295
43. K.M. Kinross, K.G. Montgomery, M. Kleinschmidt, P. Waring, I. Ivetac, A. Tikoo, M. Saad, L. Hare, V. Roh, T. Mantamadiotis, K.E. Sheppard, G.L. Ryland, I.G. Campbell, K.L. Gorringe, J.G. Christensen, C. Cullinane, R.J. Hicks, R.B. Pearson, R.W. Johnstone, G.A. McArthur, and W.A. Phillips An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice J Clin Invest 122 2012 553 557
44. K.C. Kurek, E. Howard, L.B. Tennant, J. Upton, A.I. Alomari, P.E. Burrows, K. Chalache, D.J. Harris, C.C. Trenor III, C. Eng, S.J. Fishman, J.B. Mulliken, A.R. Perez-Atayde, and H.P. Kozakewich PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes Am J Surg Pathol 36 2012 671 687
45. I. Romero, and R.C. Bast Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy Endocrinology 153 2012 1593 1602
46. E.I. Braicu, J. Sehouli, R. Richter, K. Pietzner, C. Denkert, and C. Fotopoulou Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers Br J Cancer 105 2011 1818 1824
47. L. Zhao, and P.K. Vogt Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proc Natl Acad Sci U S A 105 2008 2652 2657
48. R.L. Ross, J.M. Askham, and M.A. Knowles PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs Oncogene 32 2013 768 776
49. N.J. Bowen, S. Logani, E.B. Dickerson, L.B. Kapa, M. Akhtar, B.B. Benigno, and J.F. McDonald Emerging roles for PAX8 in ovarian cancer and endosalpingeal development Gynecol Oncol 104 2007 331 337
50. J. Li, N. Abushahin, S. Pang, L. Xiang, S.K. Chambers, O. Fadare, B. Kong, and W. Zheng Tubal origin of 'ovarian' low-grade serous carcinoma Mod Pathol 24 2011 1488 1499
51. A. Ozcan, S.S. Shen, C. Hamilton, K. Anjana, D. Coffey, B. Krishnan, and L.D. Truong PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study Mod Pathol 24 2011 751 764
52. G.X. Tong, and D. Hamele-Bena The differential expression of PAX2 and PAX8 in the ovarian surface epithelium and fallopian tubal epithelium is an important issue Am J Surg Pathol 36 2012 1099 1100
53. A. Ozcan, and L.D. Truong PAX2 and PAX8 expression in the ovarian surface epithelium and inclusion cysts Am J Surg Pathol 36 2012 1100 1102
54. H. Wang, S. Galban, R. Wu, B. Bowman, A. Witte, K. Vetter, CJ. Galban, BD. Ross, KR. Cho, and A. Rehemtulla Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma Clin Cancer Res 19 2013 158 169